Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
NCT07053800Phase 2Recruiting
- Sponsor
- Autolus Therapeutics plc
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of obecabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Autolus Therapeutics plc. Primary endpoint: Complete Renal Response at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07053800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053800.